Tislelizumab: all 398 studies that test it
Page 2 of 4. Open to participants first (214), then studies with results posted, then the rest; newest registration first within each.
- Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLCNot yet recruitingNCT06475755Phase 2
- A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerRecruitingNCT06471673Phase 1/2
- Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCNot yet recruitingNCT06456138Phase 1/2
- Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric CancerRecruitingNCT06451211Phase 2
- Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
- Neoadjuvant Comprehensive Treatment for Unresectable Esophageal CancerRecruitingNCT06430658Phase 2
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Phase 1/2
- Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine DifferentiationNot yet recruitingNCT06414915Phase 2
- Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 StudyNot yet recruitingNCT06390982Phase 2
- Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingNCT06387056Phase 2
- Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLCRecruitingNCT06379087Phase 2
- PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLCNot yet recruitingNCT06375109Phase 2
- Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.Not yet recruitingNCT06374901Phase 2
- A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Not yet recruitingNCT06364904Phase 3
- Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial CancerNot yet recruitingNCT06363708Not applicable
- Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung CancerRecruitingNCT06357598Phase 4
- A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to ImmunotherapyNot yet recruitingNCT06356675Phase 4
- TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.RecruitingNCT06353360Phase 2
- Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky TumorsRecruitingNCT06349837Phase 1
- tislelizUMaB in canceR Patients With molEcuLar residuaL DiseaseRecruitingNCT06332274Phase 3
- Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT06331845Phase 2
- A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal CancerRecruitingNCT06312982Phase 2/3
- Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06303583Phase 1/2
- Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before SurgeryRecruitingNCT06262581Phase 2
- Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06253598Phase 2
- Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJCNot yet recruitingNCT06238167Phase 2
- Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT06235918Phase 2
- A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver MetastasesNot yet recruitingNCT06218888Phase 2
- Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaRecruitingNCT06211790Phase 2
- HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)Not yet recruitingNCT06210334Phase 2
- Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric CancerNot yet recruitingNCT06197438Phase 2
- A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-TRecruitingNCT06167785Phase 2
- Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerNot yet recruitingNCT06134193Phase 2
- The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyRecruitingNCT06125080Phase 2
- Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell CarcinomaRecruitingNCT06122493Phase 2
- Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 MutationsNot yet recruitingNCT06118658Phase 2
- Tislelizumab Plus Concurrent Chemoradiation in Older With ESCCRecruitingNCT06061146Phase 2
- Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell CarcinomaRecruitingNCT06056336Phase 2
- Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain MetastaticRecruitingNCT06056115Not applicable
- Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)RecruitingNCT06032845Phase 2
- Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal CancerRecruitingNCT06017583Phase 3
- Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell CarcinomaRecruitingNCT05984342Phase 1
- Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline ChemotherapyRecruitingNCT05977673Phase 2
- XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRCRecruitingNCT05970302Phase 2
- RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 ExpressionRecruitingNCT05957757Phase 2
- Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCRecruitingNCT05941338Phase 2
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
- A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCRecruitingNCT05896059Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)RecruitingNCT05893056Phase 2
- Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II TrialRecruitingNCT05862168Phase 2
- Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal CancerNot yet recruitingNCT05841134Phase 2
- Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)RecruitingNCT05837806Phase 2
- Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)RecruitingNCT05823987Phase 2
- Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaRecruitingNCT05823311Phase 3
- Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract CarcinomaNot yet recruitingNCT05822453Phase 2
- Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.Not yet recruitingNCT05811793Not applicable
- A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUCRecruitingNCT05775874Phase 2
- Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsRecruitingNCT05771181Phase 2
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT05768932Phase 1
- Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck TumorsRecruitingNCT05758389Phase 2
- Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric CancerNot yet recruitingNCT05751265Phase 2
- Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerNot yet recruitingNCT05746728Phase 1/2
- Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerRecruitingNCT05699655Phase 2/3
- Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ AdenocarcinomaRecruitingNCT05687357Phase 2
- Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic CancerRecruitingNCT05681390Phase 2
- Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLCRecruitingNCT05611879Phase 2
- A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas CancerRecruitingNCT05604560Phase 2
- Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer PatientsRecruitingNCT05596890Phase 2
- Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck CancerRecruitingNCT05595590Phase 2
- Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerRecruitingNCT05588219Phase 2
- Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent GlioblastomaNot yet recruitingNCT05540275Phase 2
- The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)RecruitingNCT05536102Phase 2
- Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCCRecruitingNCT05533892Phase 1
- Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced CholangiocarcinomaRecruitingNCT05532059Phase 2
- A Single-arm Exploratory Study of Neoadjuvant TherapyRecruitingNCT05527808Not applicable
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerRecruitingNCT05526924Phase 1
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse AstrocytomaNot yet recruitingNCT05518994Phase 2
- Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05515315Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaRecruitingNCT05512351Phase 2
- Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical CancerRecruitingNCT05511623Phase 2
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse GlioblastomaNot yet recruitingNCT05502991Phase 2
- Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal CancerRecruitingNCT05493683Phase 2
- Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal CancerNot yet recruitingNCT05479240Phase 2
- Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal TypeRecruitingNCT05477264Phase 2
- PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced MelanomaRecruitingNCT05466474Phase 2
- Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2
- Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05449483Phase 2
- Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaRecruitingNCT05448885Phase 2
- Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder CancerNot yet recruitingNCT05445648Phase 2
- Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal CancerRecruitingNCT05420584Phase 2
- A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionRecruitingNCT05407519Phase 2
- Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder CancerRecruitingNCT05401279Phase 2
- Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCCRecruitingNCT05394415Phase 1/2
- Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular CarcinomaRecruitingNCT05366829Phase 2
- Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal CancerRecruitingNCT05360277Phase 2
- Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard TherapyNot yet recruitingNCT05350917Phase 2
- Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingNCT05319639Phase 1/2
- A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.Not yet recruitingNCT05231850Phase 2
- Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Phase 2